Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation.

abstract：:Abdominal presentations of pediatric NHL are rarely amenable to complete surgical resection. Chemotherapy is the hallmark of treatment for pediatric NHL. Treatment of various types of this disease including intra-abdominal NHL in children with various protocols have not exceeded 54 per cent two-year disease-free survi...

journal_title：Hematological oncology

authors： Abdel Hadi SS,el Taneer OM,Hussein MH,el Haddad A,el Badawi S,Mokhtar N,Hamza MR,el Mawla NG

更新日期：1991-07-01 00:00:00

abstract：:The effects of N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) on the cell cycle of murine leukemic cells (L 1210 cells) were compared with those of 1-beta-D-arabinofuranosylcytosine (ara-C), known to be effective for acute leukemia. In a cytokinetic study, a combination of Feulgen microcytofluorometry and triti...

journal_title：Hematological oncology

authors： Maruo N,Horiuchi H,Nakabo T,Kondo M,Nakamura T

更新日期：1985-01-01 00:00:00

abstract：:The cause of myelosuppression in hairy cell leukemia (HCL) has been ascribed to a reduction of the circulating progenitor cell (CPC) compartment and to suppression of hematopoiesis by TNF-alpha. The present study was performed to evaluate the inhibitory effect of hairy cells (HCs) and a possible lack of hematopoietic ...

journal_title：Hematological oncology

authors： Gasché C,Reinisch W,Schwarzmeier JD

更新日期：1993-03-01 00:00:00

abstract：:Intravascular lymphoma (IVL) is an extremely rare form of non-Hodgkin lymphoma characterized by almost exclusive growth of neoplastic lymphocytes within blood vessel lumen. IVL is morphologically characterized in most instances by large cells with B-cell lineage. IVL is an aggressive and usually disseminated disease t...

journal_title：Hematological oncology

authors： Ponzoni M,Ferreri AJ

更新日期：2006-09-01 00:00:00

abstract：:Primary bone marrow lymphoma is a rare disease and remains undiagnosed due to deceptive clinical presentation. Here, we report four cases of primary bone marrow B-cell non-Hodgkin lymphoma, which presented with cytopenias without any lymphadenopathy or organomegaly. Bone marrow examination revealed large atypical B-ce...

journal_title：Hematological oncology

authors： Bhagat P,Sachdeva MU,Sharma P,Naseem S,Ahluwalia J,Das R,Varma N,Law A,Malhotra P

更新日期：2016-03-01 00:00:00

abstract：:The objective of this research was to characterize the venetoclax exposure-efficacy and exposure-safety relationships and determine its optimal dose in elderly patients with newly diagnosed acute myeloid leukemia (AML) receiving venetoclax in combination with low intensity therapies (hypomethylating agent [HMA; azacit...

journal_title：Hematological oncology

authors： Agarwal S,Gopalakrishnan S,Mensing S,Potluri J,Hayslip J,Kirschbrown W,Friedel A,Menon R,Salem AH

更新日期：2019-10-01 00:00:00

abstract：:Because of the rarity of the disease, randomized clinical trials for multicentric Castleman disease (MCD) remain a challenge and, as a consequence, there is no established standard of care. Siltuximab is a chimeric immunoglobulin G1κ monoclonal antibody against human IL-6 which was recently approved by FDA. Eligible p...

journal_title：Hematological oncology

authors： Tonialini L,Bonfichi M,Ferrero S,Malipiero G,Nozza A,Argnani L,Zinzani PL

更新日期：2018-10-01 00:00:00

abstract：:Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma. The standard therapy for DLBCL is R-CHOP. The current 5-year overall survival is 60% to 70% using standard frontline therapy. However, the use of doxorubicin and its cardiotoxicity is a major clinical problem and preexisting cardiac disease may...

journal_title：Hematological oncology

authors： Prusila REI,Peroja P,Jantunen E,Turpeenniemi-Hujanen T,Kuittinen O

更新日期：2019-04-01 00:00:00

abstract：:From 1991 to 1997, we have treated 78 newly diagnosed patients with aggressive non-Hodgkin's lymphoma with a modified CHOP regimen in which epirubicin (60 mg/m2) was used in place of doxorubicin (50 mg/m2), i.e. CEOP (cyclophosphamide, epirubicin, vincristine and prednisolone). The median age was 41 years (range: 17 t...

journal_title：Hematological oncology

authors： Chim CS,Kwong YL,Lie AK,Lee CK,Liang R

更新日期：1998-09-01 00:00:00

abstract：:Reactivation of remote hepatitis B infection (RHBI) is an important cause of morbidity in hematopoietic cell transplant (HCT) patients. We analyzed the prevalence of RHBI in 205 patients who underwent HCT in our centre, serological events related to hepatitis B virus (HBV) reactivation and role of lamivudine prophylax...

journal_title：Hematological oncology

authors： Gupta A,Punatar S,Gawande J,Bagal B,Mathew L,Bhat V,Kannan S,Khattry N

更新日期：2016-09-01 00:00:00

abstract：:Langerhans cell histiocytosis (LCH) is rare in adults, and only a subset of these patients suffers from central nervous system (CNS) involvement. Hence, evidence-based treatment recommendations are lacking. A case of a 20-year-old student with multisystem LCH and extensive CNS involvement is described, who showed a du...

journal_title：Hematological oncology

authors： Baumann M,Cerny T,Sommacal A,Koeberle D

更新日期：2012-06-01 00:00:00

abstract：:Plasma cholesterol concentrations were determined in 83 acute myeloid leukemia patients. Mean plasma cholesterol concentration (+/- S.D.) at the time of diagnosis was 2.91 mmol/L (+/- 1.13). The percentage of AML patients having hypocholesterolemia was 90.4 per cent. The lowest cholesterol levels were observed in the ...

journal_title：Hematological oncology

authors： Zyada LE,Hassan HT,Rees JK,Ragab MH

更新日期：1990-01-01 00:00:00

abstract：:The prognosis of diffuse large B-cell lymphoma (DLBCL) having MYC rearrangement (MYC-R), including double hit lymphoma (DHL), is poor by standard immunochemotherapy. To evaluate the significance of hematopoietic stem cell transplantation (SCT) for DLBCL with MYC-R, we retrospectively analyzed Japanese SCT registry dat...

journal_title：Hematological oncology

authors： Takahashi T,Suzuki R,Yamamoto G,Nakazawa H,Kurosawa M,Kobayashi T,Okada M,Akasaka T,Kim SW,Fukuda T,Ichinohe T,Atsuta Y,Suzumiya J

更新日期：2020-09-26 00:00:00

abstract：:Smoking has been identified as a significant risk factor for acute myeloid leukaemia (AML). However, epidemiological evidence for the effect of smoking on the risk of AML among Asians is scarce. Here, we investigated the impact of smoking habits on the risk of AML by conducting a pooled analysis of 9 population-based ...

journal_title：Hematological oncology

authors： Ugai T,Matsuo K,Oze I,Ito H,Wakai K,Wada K,Nagata C,Nakayama T,Liu R,Kitamura Y,Tamakoshi A,Tsuji I,Sugawara Y,Sawada N,Sadakane A,Tanaka K,Mizoue T,Inoue M,Tsugane S,Shimazu T,Research Group for the Development a

更新日期：2018-02-01 00:00:00

abstract：:There are two different international standards for the treatment of follicular lymphoma (FL): intensified therapy followed by autologous stem-cell transplantation (ASCT) and conventional therapy in the first-line setting. However, their role remains unclear. Our aim was to define the treatment effect of intensified t...

journal_title：Hematological oncology

authors： Wang B,Ren C,Zhang W,Ma X,Xia B,Sheng Z

更新日期：2013-03-01 00:00:00

abstract：:Continuous administration of amphotericin B deoxycholate over 24 hours (24 h-D-AmB) is better tolerated than rapid infusions. However, toxicity and outcome have not been assessed in a homogenous patient population with acute myeloid leukaemia (AML). We retrospectively analysed renal function and outcome in all adult p...

journal_title：Hematological oncology

authors： Rothenbühler C,Held U,Manz MG,Schanz U,Gerber B

更新日期：2018-04-01 00:00:00

abstract：:The conventional thrombotic risk stratification in essential thrombocythemia (ET) distinguishes patients in two risk groups based on previous thrombosis and age (< or >60). The IPSET-thrombosis takes into account four risk factors: age greater than 60 years and the presence of CV risk factors, thrombosis history and J...

journal_title：Hematological oncology

authors： Santoro M,Accurso V,Mancuso S,Carlisi M,Raso S,Tarantino G,Di Piazza F,Perez A,Russo A,Siragusa S

更新日期：2019-10-01 00:00:00

abstract：:Several studies have shown that adding rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or reducing the interval between chemotherapy cycles from 3 weeks to 2 weeks improves survival in patients with diffuse large B-cell lymphoma (DLBCL). These studies prompted our group (GOTEL) to evaluate...

journal_title：Hematological oncology

authors： Rueda A,Sabin P,Rifá J,Llanos M,Gómez-Codina J,Lobo F,García R,Herrero J,Provencio M,Jara C,Grupo Oncológico para el Tratamiento y Estudio de los Linfomas (GOTEL).

更新日期：2008-03-01 00:00:00

abstract：:The thyroid gland is often involved in the development of neoplastic diseases, including lymphoproliferative disorders. The aim of this paper is to provide a comprehensive overview of the multiple interactions between lymphoma and thyroid. Through an extensive research among the literature, the relationship between ly...

journal_title：Hematological oncology

authors： Mancuso S,Carlisi M,Napolitano M,Siragusa S

更新日期：2018-02-27 00:00:00

abstract：:This is a phase II study of panobinostat, an oral pan-HDAC inhibitor, combined with rituximab in patients with relapsed diffuse large B cell lymphoma. Panobinostat was administered orally 3 times a week every other week on a 28-day cycle. Rituximab was administered weekly during the first cycle, then on Day 1 of cycle...

journal_title：Hematological oncology

authors： Barnes JA,Redd R,Fisher DC,Hochberg EP,Takvorian T,Neuberg D,Jacobsen E,Abramson JS

更新日期：2018-10-01 00:00:00

abstract：:One hundred and fifteen previously untreated adults aged over 60 years were referred to St Bartholomew's Hospital between 1978 and 1986 for management of acute myeloid leukemia (AML). Twenty-seven patients received symptomatic or palliative treatment only because combination chemotherapy was considered inappropriate. ...

journal_title：Hematological oncology

authors： Tucker J,Thomas AE,Gregory WM,Ganesan TS,Malik ST,Amess JA,Lim J,Willis L,Rohatiner AZ,Lister TA

更新日期：1990-01-01 00:00:00

abstract：:Fourteen patients with Hodgkin's disease (two previously untreated, 12 following relapse or with refractory disease) were treated with a combination chemotherapy regimen comprising chlorambucil, vinblastine, procarbazine, prednisolone, etoposide, vincristine and adriamycin administered on days 1-8. Recombinant human g...

journal_title：Hematological oncology

authors： Oza AM,Leahy M,Dorey E,Davis CL,Amess J,Horton M,Rohatiner AZ,Wrigley PF,Lister TA

更新日期：1991-11-01 00:00:00

abstract：:We assessed the efficacy of an etoposide, ifosfamide and methotrexate combination therapy (VIM) in 24 patients failing the LNH 84 protocol. Eight of these patients were refractory to the LNH 84 induction regimen, 10 were partial responders and the six remaining attained complete response after LNH 84 induction but rel...

journal_title：Hematological oncology

authors： Herbrecht R,Ortiz S,Damonte JC,Liu KL,Maloisel F,Dufour P,Bergerat JP,Oberling F

更新日期：1991-07-01 00:00:00

abstract：:Mesenchymal stem cells (MSCs) are a subset of multifunctional stem cells with self-renewal and multidirectional differentiation properties that play a pivotal role in tumor progression. MSCs are reported to exert biological functions by secreting specialized vesicles, known as exosomes, with tumor cells. Exosomes part...

journal_title：Hematological oncology

authors： Lyu T,Zhang B,Li M,Jiao X,Song Y

更新日期：2020-08-27 00:00:00

abstract：:Childhood leukemia is the commonest form of childhood cancer and represents clonal proliferation of transformed hemopoietic cells as a result of genetic changes. Molecular characterization of these changes, in particular chromosomal translocations, has yielded a wealth of information on the mechanisms of leukemogenesi...

journal_title：Hematological oncology

authors： Ma SK,Wan TS,Chan LC

更新日期：1999-09-01 00:00:00

abstract：:This study evaluates response-adapted treatment of chronic myelogenous leukaemia (CML) in chronic phase using molecular response criteria. bcr-abl/G6PDH ratios were assessed by Light-Cycler quantitative real-time polymerase chain reaction (PCR( in 277 peripheral blood samples from 33 patients, before and every 3 month...

journal_title：Hematological oncology

authors： Neumann F,Markett J,Fenk R,Pooten M,Koch A,Bruennert D,Schimkus N,Wulfert M,Royer-Pokora B,Kronenwett R,Haas R,Gattermann N

更新日期：2008-12-01 00:00:00

abstract：:Cytotoxic and DNA synthesis inhibitory effects of several iron chelators with different physicochemical properties have been tested in four myeloid leukaemic cell lines (U937, K562, ML2 and HL60). The small lipophilic chelators 8-hydroxyquinoline, tropolone and omadine at 2 X 10(-5) M, caused substantial inhibition of...

journal_title：Hematological oncology

authors： Kontoghiorghes GJ,Piga A,Hoffbrand AV

更新日期：1986-07-01 00:00:00

abstract：:To extend the clinical-pathologic description of small cleaved cell lymphoma (SCCL), we reviewed the records of 106 patients with SCCL who were treated in accordance with a policy of watchful waiting and palliative therapy. Median age was 58 years. A pure diffuse pattern was seen in only 16 per cent of cases. Stage II...

journal_title：Hematological oncology

authors： Stein RS,Greer JP,Cousar JB,Hendey GW,Wehner JH,Flexner JM,Collins RD

更新日期：1989-09-01 00:00:00

abstract：:There is a high incidence of genomic aberration of ataxia telangiectasia mutated (ATM) and genes encoding proteins involved in the ATM pathway in mantle cell lymphoma (MCL). It has been shown that poly(ADP-ribose) polymerase inhibitor (PARPi) strongly enhances the cytotoxicity of agents, causing single-strand DNA brea...

journal_title：Hematological oncology

authors： Golla RM,Li M,Shen Y,Ji M,Yan Y,Fu K,Greiner TC,McKeithan TW,Chan WC

更新日期：2012-12-01 00:00:00

abstract：:Sixty-five cases of malignant lymphoma of the nose, paranasal sinuses and hard palate were retrospectively analysed to identify the presence or absence of angiocentric lesions. We observed that the 23 patients with angiocentric lesions had a worse prognosis with a shorter duration of response and also a shorter durati...

journal_title：Hematological oncology

authors： Aviles A,Rodriguez L,Guzman R,Talavera A,Garcia EL,Diaz-Maqueo JC

更新日期：1992-05-01 00:00:00